CRISPR Therapeutics (NASDAQ:CRSP) CEO Samarth Kulkarni Sells 4,098 Shares of Company Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni sold 4,098 shares of the company’s stock in a transaction on Wednesday, October 14th. The shares were sold at an average price of $49.26, for a total transaction of $201,867.48. Following the transaction, the chief executive officer owned 259,736 shares of the company’s stock, valued at approximately $12,794,595.36. The trade was a 1.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

CRISPR Therapeutics Stock Up 2.6%

Shares of CRISPR Therapeutics stock opened at $51.52 on Friday. The company has a debt-to-equity ratio of 0.34, a current ratio of 17.85 and a quick ratio of 17.85. CRISPR Therapeutics AG has a fifty-two week low of $44.12 and a fifty-two week high of $75.06. The firm has a fifty day moving average price of $55.07 and a two-hundred day moving average price of $53.24.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Tuesday, June 30th. The company reported ($0.94) earnings per share (EPS) for the quarter. CRISPR Therapeutics had a negative return on equity of 24.39% and a negative net margin of 3,368.72%. The company had revenue of $10.18 million for the quarter. Equities analysts anticipate that CRISPR Therapeutics AG will post -4.48 EPS for the current year.

Institutional Investors Weigh In On CRISPR Therapeutics

A number of large investors have recently bought and sold shares of CRSP. AdvisorNet Financial Inc raised its position in CRISPR Therapeutics by 25.5% in the 3rd quarter. AdvisorNet Financial Inc now owns 10,673 shares of the company’s stock valued at $590,000 after purchasing an additional 2,170 shares during the last quarter. GAMMA Investing LLC lifted its position in CRISPR Therapeutics by 92.0% during the 3rd quarter. GAMMA Investing LLC now owns 1,246 shares of the company’s stock worth $69,000 after buying an additional 597 shares in the last quarter. Green Alpha Advisors LLC lifted its position in CRISPR Therapeutics by 1.8% during the 3rd quarter. Green Alpha Advisors LLC now owns 56,786 shares of the company’s stock worth $3,141,000 after buying an additional 982 shares in the last quarter. Farther Finance Advisors LLC lifted its position in CRISPR Therapeutics by 43.6% during the 3rd quarter. Farther Finance Advisors LLC now owns 11,426 shares of the company’s stock worth $632,000 after buying an additional 3,470 shares in the last quarter. Finally, Congress Asset Management Co. lifted its position in shares of CRISPR Therapeutics by 1.6% during the third quarter. Congress Asset Management Co. now owns 111,230 shares of the company’s stock worth $6,153,000 after purchasing an additional 1,777 shares in the last quarter. 69.20% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

CRSP has been the subject of a number of recent research reports. UBS Group initiated coverage on CRISPR Therapeutics in a research note on Thursday. They issued a “neutral” rating and a $52.00 target price for the company. HC Wainwright reaffirmed a “buy” rating on shares of CRISPR Therapeutics in a report on Friday, October 9th. Citigroup reissued a “market outperform” rating on shares of CRISPR Therapeutics in a research report on Monday, September 28th. Wall Street Zen upgraded shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, William Blair upgraded shares of CRISPR Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 23rd. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, CRISPR Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $65.75.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing gene-editing medicines based on CRISPR/Cas9 technology. The company aims to treat serious diseases by precisely modifying genetic material in patients’ cells, with research programs spanning hematology, oncology, autoimmune diseases, and regenerative medicine.

Its lead product, CASGEVY (exagamglogene autotemcel), is a CRISPR/Cas9-based cell therapy developed with Vertex Pharmaceuticals. CASGEVY is approved in multiple markets, including the United States, United Kingdom, and European Union, for certain patients with sickle cell disease and transfusion-dependent beta thalassemia.